Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q1 2026: Novo Nordisk 14.911, Structure Therapeutics 0.
Novo Nordisk vs Structure Therapeutics Net Worth and Market Cap
Novo Nordisk (NVO) and Structure Therapeutics (GPCR) are peers in GLP-1. Novo Nordisk reported revenue of $14.9B as of Q1 2026, compared with $0 for Structure Therapeutics. Novo Nordisk leads on revenue.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Novo Nordisk, Structure Therapeutics.| Metric | Novo Nordisk | Structure Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $14.91B | $0 |
| Cost of Revenue | $2.09B | $1.00M |
| Gross Profit | $12.82B | $-1.00M |
| Operating Income | $9.18B | $-90.00M |
| Net Income | $7.48B | $-76.00M |
| R&D Expense | $1.58B | $67.00M |
| Earnings Per Share | $1.68 | -$1.05 |
| Gross Margin | 86.0% | - |
| Operating Margin | 61.6% | - |
| Net Profit Margin | 50.1% | - |
| Free Cash Flow | $1.85B | $14.00M |
| Cumulative Free Cash Flow | $100.86B | $-469.00M |
| Operating Cash Flow | $3.71B | $15.00M |
| Cash & Equivalents | $3.25B | $316.00M |
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.